
Methods: We enrolled 39 HTLV-1 subjects (18-65 years old) without prior history or evidence of active tuberculosis at our Institute (referral center for HTLV-1 patients in Peru). TST results (positive if >10 mm) were obtained from medical records; if negative or unavailable a new TST was performed. Peripheral blood was drawn for Quantiferon TB Gold testing (IGRA) following manufacturer’s instructions (reported as positive, negative or indeterminate). Descriptive statistics and a concordance analysis were performed.Results: Clinical characteristics (Table 1) and TST-IGRA results are displayed (Table 2). Positive TST was greater among patients with positive IGRA (p value <0.05). IGRA performed well in this subjects; no indeterminate results were reported. 32 observed agreements between IGRA and TST were reported (82.05%, Kappa 0.65, standard error 0.15). Six out of seven of the discordant results were TST positive and IGRA negative. Non-discordant patients had a greater history of TB contact compared with discordant patients (10 vs. 5, p = 0.048).
Table 1. Clinical Characteristics
|
Positive IGRA (n = 17) |
Negative IGRA (n = 22) |
p value |
Male |
6 |
7 |
0.89 |
Associated HTLV-1 complication |
12 |
13 |
0.45 |
Steroid treatment in past 6 months |
3 |
1 |
0.18 |
Positive TST |
16 |
6 |
<0.05* |
History of TB contact |
6 |
9 |
0.72 |
Table 2. IGRA and TST results
|
TST |
|
||
Positive | Negative |
Total |
||
IGRA |
Positive |
16 |
1 |
17 |
Negative |
6 |
16 |
22 |
|
|
Total |
22 |
17 |
39 |
Conclusion: Moderate agreement between IGRA and TST was found. The higher TST frequency may be explained due to routine BCG vaccination policy in our country. Interestingly, prior TB contact was associated with agreement between tests. IGRA could be a reasonable alternative for LTBi diagnosis in the HTLV-1 population.

K. Luhmann,
None
D. Hoces, None
E. Gonzalez, None
T. Brewer, None
E. Gotuzzo, None
M. Montes, None